Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 759 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR How to Be Brave When Your Parent Has Cancer: A Kid’s... April 13, 2021 Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... November 18, 2020 Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... December 9, 2022 Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and... December 7, 2022 Load more HOT NEWS Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 Women Who Consume Cows’ Milk Increase Their Risk Of Breast Cancer... FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer Prostate Cancer Genomics in Racial Minority Groups
